Back to top
more

Regulus Therapeutics (RGLS)

(Delayed Data from NSDQ)

$2.42 USD

2.42
204,765

+0.15 (6.61%)

Updated Apr 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RGLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Regulus Therapeutics Inc. [RGLS]

Reports for Purchase

Showing records 141 - 160 ( 270 total )

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 141

06/28/2016

Company Report

Pages: 6

FDA Clinical Hold: Not Game Over but Raises Uncertainty for RG-101''s Clinical Timing and Profile

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 142

06/07/2016

Daily Note

Pages: 7

Full RG-101/DAA Combo Phase 2 POC SVR12 Results Suggest to Us a 4-Week HCV "Cure" Is Achievable; Reiterate OUTPERFORM and $35 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 143

06/03/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 144

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 145

05/27/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 146

05/09/2016

Daily Note

Pages: 43

May and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 147

05/05/2016

Company Report

Pages: 7

Q1 Financials: Cash Covers HCV and ATHENA Clinical Catalysts; Reiterating OUTPERFORM but Reducing PT to $35 With Updated Pipeline Assumptions

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 148

04/29/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 149

04/15/2016

Daily Note

Pages: 7

RG-101 / DAA Interim Phase 2 Results Appear Durable - Likely to Hit 12 Week Primary Endpoint in Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 150

04/08/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 11

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 151

04/01/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 4

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 152

03/28/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 153

03/16/2016

Daily Note

Pages: 5

New Data from the Phase 2 Combo Study of RG-101 for HCV to Be Presented at EASL; Reiterate OUTPERFORM and $48 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 154

03/03/2016

Industry Report

Pages: 43

March and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 155

02/22/2016

Company Report

Pages: 6

Q4:15 Financials: We Project Cash Runway Into Q3:17. Multiple Potential Clinical Catalysts in the Next 3-9 Months; Reiterate OUTPERFORM and $48 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 156

02/17/2016

Company Report

Pages: 6

Interim Results Suggest Addition of RG-101 May Reduce Curative HCV Treatment Regimens to 29 Days; Reiterate OUTPERFORM and Raising PT to $48

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 157

02/12/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 15

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 158

02/05/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 8

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 159

01/31/2016

Daily Note

Pages: 39

February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 160

01/29/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party